دورية أكاديمية
أعرض في EDS

Patient-Derived Organoids from Locally Advanced Gastric Adenocarcinomas Can Predict Resistance to Neoadjuvant Chemotherapy.

التفاصيل البيبلوغرافية
العنوان: Patient-Derived Organoids from Locally Advanced Gastric Adenocarcinomas Can Predict Resistance to Neoadjuvant Chemotherapy.
المؤلفون: Yoon C; Department of Surgery, Columbia University Irving Medical Center, Milstein Hospital Building 7-002, 177 Fort Washington Avenue, New York, NY, 10032, USA., Lu J; Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, China., Kim BJ; Department of Surgery, Columbia University Irving Medical Center, Milstein Hospital Building 7-002, 177 Fort Washington Avenue, New York, NY, 10032, USA., Cho SJ; Department of Internal Medicine, Liver Research Institute, Seoul National University Hospital, Seoul, South Korea., Kim JH; Department of Biological Science, Hyupsung University, Hwaseong-Si, South Korea., Moy RH; Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA., Ryeom SW; Department of Surgery, Columbia University Irving Medical Center, Milstein Hospital Building 7-002, 177 Fort Washington Avenue, New York, NY, 10032, USA., Yoon SS; Department of Surgery, Columbia University Irving Medical Center, Milstein Hospital Building 7-002, 177 Fort Washington Avenue, New York, NY, 10032, USA. ssy2129@cumc.columbia.edu.
المصدر: Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract [J Gastrointest Surg] 2023 Apr; Vol. 27 (4), pp. 666-676. Date of Electronic Publication: 2023 Jan 10.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 9706084 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-4626 (Electronic) Linking ISSN: 1091255X NLM ISO Abbreviation: J Gastrointest Surg Subsets: MEDLINE
أسماء مطبوعة: Publication: 2024-: [Amsterdam] : Elsevier B.V.
Original Publication: St. Louis, MO : Quality Medical Pub., c1997-
مواضيع طبية MeSH: Stomach Neoplasms*/drug therapy , Stomach Neoplasms*/surgery , Stomach Neoplasms*/pathology , Adenocarcinoma*/drug therapy , Adenocarcinoma*/surgery , Adenocarcinoma*/metabolism, Humans ; Neoadjuvant Therapy ; Organoids/metabolism ; Organoids/pathology ; Necrosis
مستخلص: Background: Patients (pts) with locally advanced gastric adenocarcinoma (LAGA) often receive neoadjuvant chemotherapy. A minority of patients do not respond to chemotherapy and thus may benefit from upfront surgery. Patient-derived organoids (PDOs) are an in vitro model that may mimic the chemotherapy response of the original tumors.
Methods: PDOs were generated from endoscopic biopsies of LAGAs prior to the initiation of chemotherapy and treated with the two chemotherapy regimens: FLOT and FOLFOX. Cell proliferation was assayed after 3-6 days. Following chemotherapy, pts underwent surgical resection, and percent pathological necrosis was determined.
Results: Successful PDOs were obtained from 13 of 24 (54%) LAGAs. Failure to generate PDOs were due to contamination (n = 3, 13%), early senescence (n = 3, 13%), and late senescence (n = 5, 21%). By H&E staining, there were significant similarities in tumor morphology and high concordance in immunohistochemical expression of 6 markers between tumors and derived PDOs. Four of 13 pts with successful PDOs did not undergo chemotherapy and surgery. For the remaining 9 pts, percent necrosis in resected tumors was ≤ 50% in 2 pts. The corresponding PDOs from these 2 pts were clearly chemoresistant outliers. The Pearson correlation coefficient between chemosensitivity of PDOs to FOLFOX (n = 2) or FLOT (n = 7) and percent tumor necrosis in resected tumors was 0.87 (p = 0.003).
Conclusions: PDOs from pts with LAGAs in many respects mimic the original tumors from which they are derived and may be used to predict resistance to neoadjuvant chemotherapy.
Synopsis: Patient-derived organoids (PDOs) can serve as personalized in vitro models of patient tumors. In this study, PDOs from locally advanced gastric cancers were able to reliably predict resistance to neoadjuvant chemotherapy.
(© 2023. The Society for Surgery of the Alimentary Tract.)
التعليقات: Expression of concern in: J Gastrointest Surg. 2024 Jun;28(6):1008. doi: 10.1016/j.gassur.2024.04.004. (PMID: 38839209)
References: Sung, H., et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021. 71(3): p. 209-249. (PMID: 10.3322/caac.2166033538338)
Cunningham, D., et al., Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 2006. 355(1): p. 11-20. (PMID: 10.1056/NEJMoa05553116822992)
Smyth, E.C., et al., Gastric cancer. Lancet, 2020. 396(10251): p. 635-648. (PMID: 10.1016/S0140-6736(20)31288-532861308)
Barker, N., et al., Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell, 2010. 6(1): p. 25-36. (PMID: 10.1016/j.stem.2009.11.01320085740)
Stange, D.E., et al., Differentiated Troy+ chief cells act as reserve stem cells to generate all lineages of the stomach epithelium. Cell, 2013. 155(2): p. 357-68. (PMID: 10.1016/j.cell.2013.09.008241201364094146)
Sato, T., et al., Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature, 2011. 469(7330): p. 415-8. (PMID: 10.1038/nature0963721113151)
Sato, T., et al., Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature, 2009. 459(7244): p. 262-5. (PMID: 10.1038/nature0793519329995)
van de Wetering, M., et al., Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell, 2015. 161(4): p. 933-45. (PMID: 10.1016/j.cell.2015.03.053259576916428276)
Baker, L.A., et al., Modeling pancreatic cancer with organoids. Trends Cancer, 2016. 2(4): p. 176-190. (PMID: 10.1016/j.trecan.2016.03.004271350564847151)
Gao, M., et al., Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues. Ann Surg Oncol, 2018. 25(9): p. 2767-2775. (PMID: 10.1245/s10434-018-6662-830003451)
Seidlitz, T., et al., Human gastric cancer modelling using organoids. Gut, 2019. 68(2): p. 207-217. (PMID: 10.1136/gutjnl-2017-31454929703791)
Yan, H.H.N., et al., A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening. Cell Stem Cell, 2018. 23(6): p. 882–897 e11.
Ganesh, K., et al., A rectal cancer organoid platform to study individual responses to chemoradiation. Nature Medicine, 2019. 25(10): p. 1607-1614. (PMID: 10.1038/s41591-019-0584-2315915977385919)
Fujii, E., et al., A simple method for histopathological evaluation of organoids. J Toxicol Pathol, 2018. 31(1): p. 81-85. (PMID: 10.1293/tox.2017-006029479145)
Janjigian, Y.Y., et al., Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann. Oncol, 2012. 23(10): p. 2656-2662. (PMID: 10.1093/annonc/mds10422689179)
Bang, Y.J., et al., Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010. 376(9742): p. 687-97. (PMID: 10.1016/S0140-6736(10)61121-X20728210)
Pietrantonio, F., et al., Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. J Clin Oncol, 2019. 37(35): p. 3392-3400. (PMID: 10.1200/JCO.19.0112431513484)
Kastner, C., et al., Organoid Models for Cancer Research-From Bed to Bench Side and Back. Cancers (Basel), 2021. 13(19).
Aberle, M.R., et al., Patient-derived organoid models help define personalized management of gastrointestinal cancer. Br J Surg, 2018. 105(2): p. e48-e60. (PMID: 10.1002/bjs.10726293411645774241)
Neal, J.T., et al., Organoid Modeling of the Tumor Immune Microenvironment. Cell, 2018. 175(7): p. 1972–1988 e16.
Vlachogiannis, G., et al., Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science, 2018. 359(6378): p. 920-926. (PMID: 10.1126/science.aao2774294724846112415)
Janjigian, Y.Y., et al., Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. Cancer Discov, 2018. 8(1): p. 49-58. (PMID: 10.1158/2159-8290.CD-17-078729122777)
Schumacher, D., et al., Heterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D cultures. PLoS Genet, 2019. 15(3): p. e1008076. (PMID: 10.1371/journal.pgen.1008076309251676457557)
فهرسة مساهمة: Keywords: Chemoresistance; Gastrectomy; Gastric cancer; Patient-derived organoids
تواريخ الأحداث: Date Created: 20230110 Date Completed: 20230406 Latest Revision: 20240606
رمز التحديث: 20240606
DOI: 10.1007/s11605-022-05568-7
PMID: 36627466
قاعدة البيانات: MEDLINE
الوصف
تدمد:1873-4626
DOI:10.1007/s11605-022-05568-7